Nodular Sclerosis Classical Hodgkin Lymphoma (NS-cHL) — Expert Care & Cure in the Majority of Patients

Nodular Sclerosis Classical Hodgkin Lymphoma (NS-cHL) is the most common subtype of Hodgkin Lymphoma, accounting for approximately 65–70% of all cases. It predominantly affects young adults between 15 and 35 years. Its defining histological feature is dense collagen bands (sclerosis) that divide affected lymph nodes into cellular nodules containing malignant Reed-Sternberg cells — particularly a characteristic variant called the 'lacunar cell'. The most clinically distinctive feature is its strong predilection for involving the mediastinum (the central chest cavity), present in approximately 80% of patients.

The strong mediastinal predilection of NS-cHL is one of its defining characteristics and is thought to reflect the origin of the malignant transformation in mediastinal thymic-related lymphoid tissue. The thymus and mediastinal lymph nodes are particularly active in young adults (the peak age for NS-cHL), and the microenvironment of these tissues may be particularly conducive to the development of Reed-Sternberg cells and the surrounding fibro-inflammatory response that characterises NS-cHL. This mediastinal involvement can cause symptoms such as cough, breathlessness, and — when severe — superior vena cava syndrome.

The standard first-line treatment for NS-cHL is ABVD chemotherapy — a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine. The number of cycles (2–6) depends on disease stage and interim PET-CT response. For advanced-stage (III–IV) NS-cHL, brentuximab vedotin + AVD (A+AVD) is approved based on ECHELON-1 data and is increasingly used. Interim PET-CT (iPET2) after 2 cycles guides treatment adaptation — allowing bleomycin to be omitted in good responders. Consolidative mediastinal radiotherapy is added for patients with initial bulky disease or residual PET-positive lesions after chemotherapy.

A+AVD is a first-line chemotherapy regimen combining brentuximab vedotin (an anti-CD30 antibody-drug conjugate) with doxorubicin (A), vinblastine (V), and dacarbazine (D) — essentially ABVD with bleomycin replaced by brentuximab vedotin. In the ECHELON-1 trial, A+AVD demonstrated improved modified progression-free survival over ABVD in advanced-stage cHL. The trade-off is that A+AVD has higher rates of peripheral neuropathy (from brentuximab) compared to ABVD, while ABVD carries greater bleomycin-related pulmonary toxicity risk. A+AVD is particularly favoured for advanced-stage, high-risk NS-cHL where its superior anti-tumour activity is most impactful.

Brentuximab vedotin (brand name Adcetris) is an antibody-drug conjugate that targets CD30 — a protein expressed on the surface of Reed-Sternberg cells in all classical Hodgkin Lymphoma subtypes including NS-cHL. It delivers a cytotoxic drug (MMAE) directly to CD30-expressing cells. It is approved in three settings for NS-cHL: (1) combined with AVD as first-line therapy for advanced-stage cHL (A+AVD); (2) as maintenance therapy for up to 1 year after autologous SCT in patients at high risk of relapse (AETHERA trial); and (3) for relapsed or refractory cHL after at least 2 prior lines of therapy.

Young adults treated for NS-cHL — particularly those receiving mediastinal radiotherapy — face important long-term risks: cardiovascular disease (heart valve problems, coronary artery disease, cardiomyopathy from mediastinal radiation and anthracyclines); secondary cancers (breast cancer in women receiving chest radiotherapy aged under 30 — this risk is substantial and requires MRI surveillance; secondary AML/MDS from alkylating agents); hypothyroidism (from neck or mediastinal radiotherapy); and pulmonary fibrosis (from bleomycin, particularly when combined with radiotherapy). These risks are why specialist lymphoma centres focus intensively on radiotherapy-sparing strategies (iPET2-guided bleomycin omission, treatment de-escalation) and why long-term survivorship care plans are essential for all NS-cHL survivors.

Yes — NS-cHL is one of the most curable cancers in young adults. With modern ABVD-based or A+AVD chemotherapy and PET-adapted approaches, cure rates for early-stage favourable NS-cHL exceed 90%. Even for advanced-stage disease, the majority of patients achieve long-term remission with appropriate first-line treatment. The minority of patients who relapse can often be effectively salvaged with platinum-based chemotherapy and autologous SCT, achieving cure or prolonged remission. PD-1 checkpoint inhibitors (nivolumab, pembrolizumab) provide excellent disease control in further relapsed disease.

For relapsed or refractory NS-cHL, the standard approach for transplant-eligible patients is platinum-based salvage chemotherapy followed by autologous stem cell transplantation (auto-SCT). Brentuximab vedotin maintenance after auto-SCT reduces the risk of further relapse. For patients who are not transplant candidates or who relapse after transplant, nivolumab and pembrolizumab (PD-1 checkpoint inhibitors) achieve response rates of approximately 65–70% and provide meaningful, often durable disease control. The combination of nivolumab + brentuximab vedotin is also approved for transplant-ineligible relapsed/refractory cHL.

Yes. CancerFax connects NS-cHL patients with specialist lymphoma haematologists, radiation oncologists experienced in mediastinal ISRT techniques, and fertility specialists — providing expert biopsy review, PET-CT staging interpretation, second opinion coordination on A+AVD vs ABVD selection and mediastinal radiotherapy decisions, access to brentuximab vedotin maintenance and PD-1 inhibitor programmes, proton therapy centre coordination for mediastinal disease, and clinical trial identification. We coordinate with specialist lymphoma centres in India, Germany, South Korea, the UAE, and other countries internationally.